Search results
Added:
3 years ago
Atrial fibrillation (AF) is the most frequently encountered arrhythmia in clinical practice.1,2 The prevalence of AF in the United States ranges from 2.7 to 6.1 million, with 5.6 to 12 million additional cases projected by 2050.1 Medicare spending for new AF diagnoses has reached $15.7 billion per year as extrapolated from a 2004–2006 dataset, primarily driven by its complications (e.g. stroke,…
View more
Added:
1 year ago
EHRA 2023 — Investigator, Prof Nicolas Doll (Schuechtermann-Klinik, DE) joins us to discuss the take-home messages from the international prospective randomised multi-centre CEASE-AF study (NCT02695277).
In a randomized controlled trial, 146 patients were enrolled to compare the safety, efficacy, and quality of life outcomes of a combined epicardial surgical plus endocardial catheter technique…
View more
Added:
3 years ago
Catheter ablation (CA) is a widely used first-line treatment for AF. Randomised controlled trials (RCTs) have shown its superiority to pharmacological treatment in terms of symptom control, rhythm control and mortality in selected patients; observational studies have also suggested a decreased risk of stroke.1,2 Pulmonary vein isolation (PVI) is the standard endpoint, but studies have reported…
View more
Added:
3 years ago
The best clinical approach to managing asymptomatic patients with ventricular pre-excitation has yet to be established. The clinical benefit of identifying and treating asymptomatic patients at risk of sudden cardiac death (SCD) has been debated since catheter ablation became effective and safe for the treatment of accessory pathways (APs). Data supporting current recommendations are mostly…
View more
Added:
3 years ago
Although the exact circuit of atrioventricular nodal re-entrant tachycardia (AVNRT) still eludes us, AVNRT is the most common regular arrhythmia in humans, and therefore the most commonly encountered during ablation attempts for regular tachycardias.1–4 Catheter ablation for AVNRT is the current treatment of choice in symptomatic patients. It reduces arrhythmia-related hospitalisations and costs,…
View more
Added:
5 years ago
Dr Afzal Sohaib spoke with Dr Dipak Kotecha about the FAST trial - Thoracoscopic vs catheter ablation for atrial fibrillation
Fillmed by Radcliffe Cardiology on-site at EHRA 2018 in Barcelona, ES
View more
Added:
2 years ago
Added:
3 years ago
Over the last 30 years, the role of catheter ablation for treating a wide range of arrhythmias has increased dramatically. The electrophysiological substrates of the more straightforward arrhythmias (such as atrio-ventricular reciprocating tachycardia and atrio-ventricular nodal re-entry tachycardia) have now been well defined and excellent long-term success rates can be achieved at minimal risk…
View more
Added:
7 months ago
ESC 2023 — We are joined onsite by Prof Christian Sohns and Prof Philipp Sommer (Heart and Diabetes Centre, Bad Oyenhausen, DE) to discuss the findings from the CASTLE-HTx trial (NCT04649801).
CASTLE-HTx (Heart and Diabetes Center North-Rhine Westfalia) aimed to determine if atrial fibrillation ablation has beneficial effects on mortality in patients with end-stage heart failure, who are…
View more
Added:
3 years ago
Heart failure (HF) and AF are two conditions that are increasing in prevalence worldwide.1,2 They frequently co-exist and in recent years, the clinical and physiological intersection between arrhythmia and HF has become an area of renewed interest, particularly as interventional treatments for rhythm disorders have advanced and moved into the mainstream of cardiac management. In particular, AF,…
View more
« First